Progyny (PGNY) Stock Price, News & Analysis

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PGNY shares.
View PGNY analyst ratings or view top-rated stocks.

10 Wall Street analysts have issued 1 year target prices for Progyny's stock. Their PGNY share price targets range from $43.00 to $57.00. On average, they anticipate the company's share price to reach $48.30 in the next twelve months. This suggests a possible upside of 43.4% from the stock's current price.
View analysts price targets for PGNY or view top-rated stocks among Wall Street analysts.

Progyny's stock was trading at $37.18 at the beginning of 2024. Since then, PGNY stock has decreased by 9.4% and is now trading at $33.69.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our PGNY earnings forecast.

Progyny, Inc. (NASDAQ:PGNY) issued its earnings results on Tuesday, February, 27th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.09 by $0.04. The firm earned $269.94 million during the quarter, compared to the consensus estimate of $274.08 million. Progyny had a net margin of 5.70% and a trailing twelve-month return on equity of 12.64%. The firm's revenue was up 26.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.03 EPS.

ETFs with the largest weight of Progyny (NASDAQ:PGNY) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), Aztlan Global Stock Selection DM SMID ETF (AZTD), Janus Henderson Small Cap Growth Alpha ETF (JSML), BNY Mellon Women's Opportunities ETF (BKWO), SPDR S&P Health Care Services ETF (XHS), Harbor Corporate Culture Small Cap ETF (HAPS), Thrivent Small-Mid Cap ESG ETF (TSME) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

Progyny updated its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of 0.330-0.350 for the period, compared to the consensus earnings per share estimate of 0.180. The company issued revenue guidance of $285.0 million-$292.0 million, compared to the consensus revenue estimate of $314.0 million.

25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD).

Progyny (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Progyny's stock is owned by many different institutional and retail investors. Top institutional shareholders include Congress Asset Management Co. MA (1.05%), International Assets Investment Management LLC (0.16%), Los Angeles Capital Management LLC (0.05%), Radnor Capital Management LLC (0.04%) and NBC Securities Inc. (0.03%). Insiders that own company stock include Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Mark S Livingston, Michael E Sturmer, Norman Payson, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc.
View institutional ownership trends.

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.